According to a recent LinkedIn post from Resolution Therapeutics, CEO Amir Hefni discussed the company’s EMERALD clinical program and its focus on regenerative macrophage therapies in a BiotechTV interview. The post indicates that the interim cohort for the EMERALD study has been fully recruited, with active enrollment occurring across 15 trial sites split between the U.K. and Spain.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that Resolution Therapeutics is targeting an interim data readout for EMERALD in Q3 2026, with an interim analysis mentioned in the interview as expected toward the end of Q3 this year. For investors, the emphasis on regenerative macrophages and clear clinical timelines may signal a maturing pipeline in liver or immune-related regenerative medicine, where positive interim data could serve as a key value inflection point.
The concentration of 15 trial sites across two European markets may also indicate a manageable but meaningful trial footprint, supporting more efficient patient recruitment and data collection. If EMERALD advances as suggested, Resolution Therapeutics could strengthen its position within the emerging cell-based regenerative therapies segment, potentially improving its attractiveness to larger biopharma partners or late-stage investors.